Inhibiting TYRO3 attenuates iron-mediated cell death in cancer cells, resulting in a shift in the M1/M2 macrophage ratio and creating a tumor-promoting environment.335 Conversely, inhibiting TYRO3 promotes tumor ferroptosis, alters the M1/M2 macrophage balance, and improves the tumor response to PD-1 therapy.335 Several studies have elucidated the complex relationship between TAMs and ferroptosis. This evidence concerns the gene TYRO3 and neoplasm.